FIELD: medicine.
SUBSTANCE: group of inventions relates to the diagnosis and prognosis of Lyme disease. The composition for the diagnosis or prognosis of Lyme disease contains 5 isolated FlaB peptides with Borrelia T-cell epitopes having amino acid sequences SEQ ID NO: 1-5; 13 isolated DbpB peptides with a Borrelia T-cell epitope having the amino acid sequence SEQ ID NO:6-18; 13 isolated peptides p66 with a T-cell epitope of Borrelia having amino acid sequences SEQ ID NO:19-31; 2 isolated OspC peptides with a Borrelia T-cell epitope having the amino acid sequences SEQ ID NO:32-33. Also disclosed is a method for detecting Lyme disease in a subject, a composition containing a set of nucleic acids encoding peptides, a set of nucleic acid-based vectors for host cell transformation, and a host cell for the expression of nucleic acids.
EFFECT: improved diagnostic and prognostic assessment of Lyme disease.
43 cl, 1 dwg, 7 tbl, 1 ex
Title | Year | Author | Number |
---|---|---|---|
DNA ANTIBODY CONSTRUCTIONS FOR USE AGAINST LYME DISEASE | 2017 |
|
RU2813829C2 |
VIRUS-LIKE PARTICLES WITH HIGH-DENSITY COATING FOR INDUCTION OF ANTIBODY EXPRESSION | 2017 |
|
RU2813282C2 |
CHIMERIC OSPA GENES, PROTEINS AND THEIR APPLICATION METHODS | 2011 |
|
RU2773402C2 |
VARIANT CD3 BINDING DOMAINS AND THEIR USE IN COMBINATION THERAPY FOR TREATMENT OF DISEASES | 2019 |
|
RU2810222C2 |
T-CELL RECEPTOR CONSTRUCTS AND THEIR USE | 2019 |
|
RU2785954C2 |
FUSION CONSTRUCTION CONTAINING CELL PENETRATING PEPTIDE, POLYEPITOPE AND TLR PEPTIDE AGONIST, INTENDED FOR TREATMENT OF CANCER | 2017 |
|
RU2807135C2 |
METHOD OF PREVENTION OR TREATMENT OF PERIPHERAL NEUROPATHY OR PAIN ACCOMPANYING DISEASE IN WHICH PERIPHERAL NEUROPATHY OR ASTROCYTE DISORDER IS IDENTIFIED | 2019 |
|
RU2822199C2 |
PEPTIDE IMMUNOGENS TARGETING INTERLEUKIN 6 (IL-6) AND COMPOSITIONS THEREOF FOR IMMUNOTHERAPY OF DISEASES AFFECTED BY IMPAIRED IL-6 REGULATION | 2019 |
|
RU2780161C1 |
CHIMERIC ANTIGENE RECEPTORS TARGETTING FLT3 | 2018 |
|
RU2820859C2 |
ISOLATED RECOMBINANT VIRUS BASED ON INFLUENZA VIRUS FOR INDUCING SPECIFIC IMMUNITY TO INFLUENZA VIRUS AND/OR PREVENTING DISEASES CAUSED BY INFLUENZA VIRUS | 2021 |
|
RU2813150C2 |
Authors
Dates
2021-06-21—Published
2016-09-15—Filed